Pharmacelsus and Insilico Biotechnology Join Forces to Deliver Combined Solutions in Preclinical Drug Development

10 February 2014

(Saarbrücken/Stuttgart) – Pharmacelsus, Germany’s market-leading preclinical CRO and Insilico Biotechnology, leading provider of innovative solutions around the simulation of biological processes, combine their expertise in preclinical characterization of drug-candidates.

The two companies’ new joint service exploits Pharmacelsus’ experimental expertise and Incilico's skills in the fields of modeling and simulation, yielding end-to-end solutions for the testing of potential drugs. During the process, a minimum amount of empirical in vitro data is generated. These data are then evaluated using computational models in order to predict the effects of the API on the human body or the outcome of preclinical animal trials with high accuracy. The integrated approach reduces the required experimental effort, particularly in animal testing, simplifies the selection of promising drug candidates, and reduces risk, time, and cost of the drug development process.

The combined portfolio includes the prediction of pharmacokinetic properties and equivalent in vivo doses both in preclinical species and in humans on the basis of in vitro ADMET data. This allows customers to develop the optimal protocol for necessary animal studies. Additionally, customer’s challenging problems in research can be tackled applying the integrated knowledge base in preclinical drug development, bioanalytics, modeling and simulation.

"The alliance with Pharmacelsus enables Insilico to offer new packages comprising experimental services and simulation solutions. Pharmacelsus is the ideal partner for this joint enterprise", said Klaus Mauch, CEO of Insilico. Dr. Christine Batzl-Hartmann, Pharmacelsus’ CEO, added: "We are glad about the fact that the long-standing cooperation between Pharmacelsus and Insilico will now mount a combined service, and we are confident that this service will provide an aid in our customers’ preclinical research."

Contact

Insilico Biotechnology AG
Dirk Rathfelder | Business Development
T +49 711 460 594-19
F +49 711 460 594-10
dirk.rathfelder [at] insilico-biotechnology.com

Pharmacelsus GmbH
Dr. Christine Batzl-Hartmann | CEO
T +49 681 3946-7510
F +49 681 3946-7511
batzl [at] pharmacelsus.de